Kura Oncology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 24, 2020, details the results of Kura Oncology, Inc.'s Annual Meeting of Stockholders. The company is incorporated in Delaware and trades on The Nasdaq Global Select Market under the symbol KURA.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes rather than financial performance.
Material Changes and Voting Results
As of the record date (April 27, 2020), there were 45,433,279 shares outstanding, with 37,407,261 shares present or represented by proxy. Stockholders approved the following proposals:
- Election of Directors: Steven H. Stein, M.D., Mary T. Szela, and Diane Parks were elected as Class III directors.
- Auditor Ratification: Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
- Executive Compensation: Stockholders approved, on an advisory basis, the compensation paid to named executive officers.
- Compensation Frequency: Stockholders approved, on an advisory basis, the recommendation to solicit stockholder advisory approval of executive compensation annually (every year).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the reporting of the Annual Meeting vote tallies.
Key Facts for Investor Verification
- Verify the tenure of the newly elected Class III directors (Steven H. Stein, Mary T. Szela, Diane Parks) until the 2023 Annual Meeting.
- Confirm the continued engagement of Ernst & Young LLP as the independent auditor for the 2020 fiscal year.
- Note the strong stockholder support for annual executive compensation advisory votes (31,481,954 votes for 1-year frequency).
- Review the proxy statement for detailed executive compensation figures referenced in Proposal 3.